Overview
Immunotherapy uses your body's immune system to fight cancer, while targeted therapy blocks specific molecules that drive tumour growth. Both approaches have transformed outcomes in lung, kidney, melanoma, breast, colon and many other cancers.
Dr. Ravi Jaiswal ensures every eligible patient gets appropriate biomarker testing (PD-L1, EGFR, ALK, HER2, MSI, BRAF and more) so the right drug reaches the right patient.
How we treat it
- PD-1 / PD-L1 checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab)
- CTLA-4 inhibitors (ipilimumab) in combination therapy
- Tyrosine kinase inhibitors matched to genetic mutations
- Monoclonal antibodies (trastuzumab, cetuximab, rituximab)
- Biomarker testing and molecular tumour board review
Frequently asked questions
Is immunotherapy better than chemotherapy?+
For some cancers, yes — but not all. The best treatment depends on tumour type and biomarkers. We often combine both for maximum benefit.
What are the side effects of immunotherapy?+
Most patients tolerate it very well. The main risk is immune-related inflammation of organs like the thyroid, lungs or gut, which is manageable when caught early.
This page is for information only and does not replace a medical consultation. Please speak to a qualified doctor for advice specific to your condition.